– Top-tier investor syndicate co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years and Cantos Ventures. – Financing will be used to develop an AI-first protein ...

Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI ...

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd.

Nabla Bio has entered a new multi-year research collaboration with Takeda to advance the AI-driven design of protein therapeutics. Nabla Bio will receive an upfront payment along with research funding ...

Nabla Bio, a Boston, Massachusetts based startup, announced a $11 million seed round on Monday. The company, founded in May 2020, is looking to enter the increasingly competitive space of antibody ...